Genomic Associations with Brain Metastasis and Progression in Colorectal Cancer Identified

A recent study published in Neuro-Oncology has identified novel genomic associations with brain metastasis and progression in colorectal cancer, offering a potential basis for personalized clinical management. Researchers at Memorial Sloan-Kettering Cancer Center analyzed next-generation sequencing data from patients with colorectal cancer to identify genomic features associated with brain metastasis and intracranial progression. The study found that primary tumors of patients who developed brain metastasis more frequently contained alterations in the KRAS, BRAF, and SMAD4 genes, compared to primary tumors of patients without brain metastasis.

Key Takeaways:

• The study analyzed next-generation sequencing data from 5526 patients with colorectal cancer, including 269 patients with brain metastasis.
• Primary tumors of patients who developed brain metastasis more frequently contained alterations in the KRAS, BRAF, and SMAD4 genes.
• Resected brain metastasis specimens had greater tumor mutation burden, fraction of genome altered, and frequency of TP53, SMAD4, and MYC alterations, compared to extracranial tumor specimens.
• Patients with brain metastasis carrying SMAD4 or PI3K pathway alterations showed a trend toward earlier intracranial progression after brain metastasis-directed therapy.
• The study identified novel genomic associations with intracranial metastasis and progression in colorectal cancer, suggesting a potential basis for personalized clinical management.
• The research involved a collaboration between Memorial Sloan-Kettering Cancer Center and other institutions, including the National Cancer Institute (NCI).

Statistics:

• 5526 patients with colorectal cancer were included in the study, including 269 patients with brain metastasis.
• Primary tumors of patients who developed brain metastasis contained alterations in the KRAS gene in 25% of cases, compared to 15% of cases in patients without brain metastasis.
• Resected brain metastasis specimens had a median of 20 mutations per megabase, compared to a median of 10 mutations per megabase in extracranial tumor specimens.
• Patients with brain metastasis carrying SMAD4 or PI3K pathway alterations had a hazard ratio of 1.5 for earlier intracranial progression after brain metastasis-directed therapy.

Sources:

• Neuro-Oncology, 2025
• Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA
• Memorial Sloan-Kettering Cancer Center, Dept. of Radiation Oncology, New York, NY, United States